← All trials
NCT05392764
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2022
- Primary completion
- Apr 1, 2023
- Completion date
- Apr 1, 2023
- First posted
- May 26, 2022
- Last posted
- Nov 15, 2022
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Juntendo UniversityLead sponsor
- Boehringer IngelheimCollaborator
- Juntendo UniversityOverall official - principal investigator
- Juntendo UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.